Research ArticlePerspective
Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper
Raymond Evers, Shannon Dallas, Leslie J. Dickmann, Odette A. Fahmi, Jane R. Kenny, Eugenia Kraynov, Theresa Nguyen, Aarti H. Patel, J. Greg Slatter and Lei Zhang
Drug Metabolism and Disposition September 2013, 41 (9) 1598-1609; DOI: https://doi.org/10.1124/dmd.113.052225
Raymond Evers
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Shannon Dallas
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Leslie J. Dickmann
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Odette A. Fahmi
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Jane R. Kenny
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Eugenia Kraynov
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Theresa Nguyen
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Aarti H. Patel
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
J. Greg Slatter
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
Lei Zhang
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey (R.E., T.N.); Drug Metabolism and Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania (S.D.); Pharmacokinetics and Drug Metabolism (L.J.D.), and Clinical Pharmacology-Early Development (J.G.S.), Amgen Inc., Seattle, Washington; Pharmacokinetics, Dynamics, Drug Metabolism, Pfizer, Groton, Connecticut (O.A.F.); Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (J.R.K.); Worldwide Research and Development, Pfizer, La Jolla, California (E.K.); Research and Development, GlaxoSmithKline, Hertfordshire, United Kingdom (A.H.P.); and Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (L.Z.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticlePerspective
Cytochrome P450–Related Therapeutic Protein Drug Interaction White Paper
Raymond Evers, Shannon Dallas, Leslie J. Dickmann, Odette A. Fahmi, Jane R. Kenny, Eugenia Kraynov, Theresa Nguyen, Aarti H. Patel, J. Greg Slatter and Lei Zhang
Drug Metabolism and Disposition September 1, 2013, 41 (9) 1598-1609; DOI: https://doi.org/10.1124/dmd.113.052225
Research ArticlePerspective
Cytochrome P450–Related Therapeutic Protein Drug Interaction White Paper
Raymond Evers, Shannon Dallas, Leslie J. Dickmann, Odette A. Fahmi, Jane R. Kenny, Eugenia Kraynov, Theresa Nguyen, Aarti H. Patel, J. Greg Slatter and Lei Zhang
Drug Metabolism and Disposition September 1, 2013, 41 (9) 1598-1609; DOI: https://doi.org/10.1124/dmd.113.052225
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement